2025-03-04 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis

**0) Introduction:** This report analyzes Colgate-Palmolive Co (CL), a leading manufacturer and marketer of household and personal care products.  The analysis uses provided financial data, including performance metrics, price movements, and technical indicators.

**1) Performance Comparison with S&P 500 (VOO):**

Colgate-Palmolive's cumulative return of 39.83% significantly underperformed the S&P 500's return of 116.17% over the analyzed period. The difference is a considerable -76.3%, placing it in the 14th percentile of the historical range of underperformance (-90% to +8.2%).  This suggests CL has lagged the broader market considerably.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 13.0% | 4.6% | -15.0% | 0.1 | 52.1 |
| 2016-2018  | -12.0% | 8.5% | -30.0% | 0.3 | 42.1 |
| 2017-2019  | 9.0% | 8.5% | -21.0% | 0.2 | 50.0 |
| 2018-2020  | 21.0% | 8.5% | -6.0% | 0.7 | 63.5 |
| 2019-2021  | 32.0% | 7.3% | -39.0% | 1.0 | 64.9 |
| 2020-2022  | 7.0% | 9.3% | -2.0% | 1.0 | 61.4 |
| 2021-2023  | 3.0% | 9.3% | -20.0% | 1.0 | 63.7 |
| 2022-2024  | 13.0% | 9.3% | -20.0% | 1.0 | 74.2 |
| 2023-2025  | 25.0% | 8.8% | 0.5 | 1.0 | 74.8 |

The alpha values are consistently negative, indicating underperformance relative to the benchmark. The beta values are generally around 1, suggesting similar volatility to the market. However, the negative alpha consistently points to underperformance.


**2) Recent Price Movement:**

* **Closing Price:** $91.17
* **Last Market Price:** $92.25 (a $1.08 increase)
* **5-Day Moving Average:** $90.79
* **20-Day Moving Average:** $87.91
* **60-Day Moving Average:** $89.68

The price is above all three moving averages, suggesting a potential short-term uptrend. The recent price increase is notable.


**3) Technical Indicators:**

* **RSI (64.75):**  Indicates the stock is neither overbought nor oversold, suggesting a neutral momentum.
* **PPO (0.62):** A positive PPO suggests bullish momentum.
* **20-Day Relative Strength Change (+4.9):**  Indicates a recent short-term upward trend.

The price increase of $1.08 from the previous close reflects a positive market shift, supporting the indicators showing short-term upward momentum.


**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-10-25 | $0.9 | $5.03B       |
| 2024-07-26 | $0.89 | $5.06B       |
| 2024-04-26 | $0.83 | $5.07B       |
| 2023-10-27 | $0.86 | $4.92B       |
| 2024-10-25 | $0.86 | $4.92B       |

There appears to be an error in the data, showing duplicate entries for October 25th, 2024.  Excluding the duplicate, revenue remains relatively stable, while EPS shows slight growth.  More detailed analysis is needed to draw significant conclusions.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.95B | 60.30% |
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |

Revenue is relatively stable, with slight fluctuations. Profit margins are consistently high and around 60%.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $0.21B | 348.58% |
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |

Equity and ROE show significant volatility.  The high ROE figures need further investigation to understand the underlying drivers.  Inconsistencies in ROE require deeper financial statement analysis to determine validity.


**6) Overall Conclusion:**

Colgate-Palmolive (CL) has significantly underperformed the S&P 500 over the analyzed period, exhibiting consistently negative alpha.  While recent price action suggests a short-term uptrend, supported by technical indicators, the long-term underperformance and volatility in financial metrics raise concerns. The high and inconsistent ROE values require further investigation. A long-term investment strategy should consider the potential for continued underperformance relative to the market. The -280.3% expected return relative to the S&P 500 is extreme and likely erroneous, requiring a review of the calculation methodology.  Further analysis, including a deeper dive into the financial statements and a thorough review of the provided data, is needed to form a comprehensive investment opinion.  The data inconsistencies need to be addressed before drawing final conclusions.
